This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (150)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

PHILIP H. HENNEMAN, M.D.; STANLEY WALLACH, M.D.

AMA Arch Intern Med. 1957;100(5):715-723.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

I. Introduction

Postmenopausal osteoporosis is not generally recognized as a common cause for back pain. Even when recognized it is often accepted as the normal state of the spine for the age. Finally, even when postmenopausal osteoporosis is recognized and the need for therapy appreciated, effective therapy is withheld on the bases that osteoporosis is a self-limited disease, that hormone therapy is dangerous, particularly in regard to stimulation of cancerogenesis, and that hormone therapy is too complicated for general use. It has been our experience that osteoporosis is a common disease state of postmenopausal women, that it may produce severe and disabling back pain, and that estrogen and androgen therapy is effective, safe, and simple. This paper reviews the nature of osteoporosis, summarizes the published balance studies in which estrogen and androgen therapy can be evaluated, and indicates the highlights of our own experience in the prolonged estrogen treatment of . . . [Full Text PDF of this Article]

Author Affiliations
Boston

From the Medical Service of the Massachusetts General Hospital and the Department of Medicine, Harvard Medical School. Instructor in Medicine, Harvard Medical School, Assistant in Medicine, Massachusetts General Hospital (Dr. Henneman); Research and Clinical Fellow in Medicine, Harvard Medical School and Massachusetts General Hospital (Dr. Wallach).

Footnotes
Submitted for publication June 6, 1957.

These studies were supported in part by grants to Dr. Fuller Albright from the American Cancer Society on recommendation of the Committee on Growth of the National Research Council, from the United States Public Health Service, and from Ayerst Laboratories, Inc.

Read in the Symposium on the Use of Androgens and Estrogens and Their Metabolic Effects before the Joint Meeting of the Section on Experimental Medicine and Therapeutics and the Section on

Internal Medicine at the 106th Annual Meeting of the American Medical Association, New York, June 6, 1957.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?